Evidence map›Paper›PMID 35072751›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2022

The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy.

Sara Pedraza, Alexander P Seiffert, Pilar Sarandeses, Beatriz Muñoz-Lopez, Enrique J Gómez, Patricia Sánchez-González, José F Pérez-Regadera

Open access · hybridAbstract read
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. [Diagnostics (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Value of [Scientific reports · 2023
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Sara PedrazaFaculty of Medicine, Universidad Complutense de Madrid and Department of Radiation Oncology, Hospital Universitario 12 de Octubre, Avenida de Córdoba, s/n. 28041, Madrid, Spain. sara.pedraza@salud.madrid.org.ORCID 0000-0001-9387-1937
Alexander P SeiffertBiomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain.ORCID 0000-0001-7274-244X
Pilar SarandesesDepartment of Nuclear Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-1415-345X
Beatriz Muñoz-LopezBiomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain.ORCID 0000-0002-5028-641X
Enrique J GómezBiomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain.ORCID 0000-0001-6998-1407
Patricia Sánchez-GonzálezBiomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain.ORCID 0000-0001-9871-0884
José F Pérez-RegaderaFaculty of Medicine, Universidad Complutense de Madrid and Department of Radiation Oncology, Hospital Universitario 12 de Octubre, Avenida de Córdoba, s/n. 28041, Madrid, Spain.ORCID 0000-0003-3525-3967
Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESUniversidad Complutense de Madrid · ESUniversidad Politécnica de Madrid · ESHospital Universitario 12 De Octubre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the study was to assess the impact of clinical and metabolic parameters derived from

methodsPatients with LACC of stage IB2-IVA treated by primary radiochemotherapy followed by brachytherapy were enrolled in this retrospective study. Indexes derived from standardized uptake value (SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and textural features of the primary tumor were measured for each patient. Overall survival (OS) and recurrence-free survival (RFS) rates were calculated according to Kaplan-Meier and survival curves were compared using the log-rank test. Uni- and multivariate analyses were performed using the Cox regression model.

resultsA total of 116 patients were included. Median follow-up was 58 months (range: 1-129). A total of 36 (31%) patients died. Five-year OS and RFS rates were 69 and 60%, respectively. Univariate analyses indicated that FIGO stage, the presence of hydronephrosis, high CYFRA 21.1 levels, and textural features had a significant impact on OS and RFS. MTV as well as SCC-Ag concentration were also significantly associated with OS. On multivariate analysis, the presence of hydronephrosis, CYFRA 21.1, and sphericity were independent prognostics factors for OS and RFS. Also, SCC-Ag level, MTV, and GLZLM (gray-level zone length matrix) ZLNU (zone length non-uniformity) were significantly associated with OS.

conclusionClassical prognostic factors and tumor heterogeneity on pretreatment PET/CT were significantly associated with prognosis in patients with LACC.

Indexed as

HydronephrosisUterine Cervical NeoplasmsAntigens, NeoplasmChemoradiotherapyFemaleFluorodeoxyglucose F18HumansKeratin-19Positron-Emission TomographyPositron Emission Tomography Computed TomographyPrognosisRadiopharmaceuticalsRetrospective StudiesTumor Burdenantigen CYFRA21.1Antigens, NeoplasmFluorodeoxyglucose F18Keratin-19RadiopharmaceuticalsChemoradiotherapyPositron emission tomography–computed tomographyPrognosisUterine cervical neoplasms

Identifiers

PMID35072751
PMCPMC9402502
OpenAlexW4207027594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.